Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Apoteket omstrukturering AB in connection with the sale of pharmacies
Mandate

Vinge has advised Apoteket omstrukturering AB in connection with the sale of pharmacies

November 10, 2009

Vinge has advised Apoteket Omstrukturering AB in connection with the reregulation of the Swedish pharmacy market and in connection with the disposal through Apoteket AB (publ) of 8 so-called cluster companies consisting of a total of 465 pharmacies to Kronans Droghandel/KF, Altor, Priveq/Investor Growth Capital and Segulah for a total purchase price of approximately SEK 5.9 billion.

The Vinge team was led by Carl Gustaf De Geer and Henrik Wenckert and included associates from different practice areas such as M&A, Banking & Finance, EU &Antitrust, IT/Telecom, Employment & Benefits, Real Estate, Intellectual Property and also entailed regulatory issues regarding the pharmaceuticals legislation including licensing on the pharmacy market.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025